Literature DB >> 28471273

Gaze-controlled communication technology for children with severe multiple disabilities: Parents and professionals' perception of gains, obstacles, and prerequisites.

Eva Holmqvist1,2, Gunilla Thunberg2, Marie Peny Dahlstrand1,3.   

Abstract

The aim of this study was to explore parents' and professionals' thoughts of how a gaze-controlled computer can be beneficial to children with severe multiple disabilities. All systems were provided primarily for symbol-based communication, but were also used for other purposes such as play, leisure and school activities. A further aim was to investigate factors affecting usability, specifically for communication. The study used a qualitative approach, involving content analysis of semistructured interviews with the children's key persons (N = 11). The analysis yielded three categories and twelve subcategories. There were gains for the children in terms of empowerment, social interaction, learning opportunities and efficient computer use. Inaccessibility, liability issues and technical failure were seen as obstacles, while the prerequisites included time, collaboration, stimulating content, know-how and opportunities. To sum up, this study suggests that gaze-controlled technology can provide children who have multiple disabilities involving severe motor dysfunction and communicative and cognitive problems with new opportunities to communicate, interact and perform activities independently, as long as conditions are right.

Entities:  

Keywords:  augmentative and alternative communication; communication; computer access; pediatrics; usability

Mesh:

Year:  2017        PMID: 28471273     DOI: 10.1080/10400435.2017.1307882

Source DB:  PubMed          Journal:  Assist Technol        ISSN: 1040-0435


  1 in total

1.  Stakeholder consensus for decision making in eye-gaze control technology for children, adolescents and adults with cerebral palsy service provision: findings from a Delphi study.

Authors:  Petra Karlsson; Tom Griffiths; Michael T Clarke; Elegast Monbaliu; Kate Himmelmann; Saranda Bekteshi; Abigail Allsop; René Pereksles; Claire Galea; Margaret Wallen
Journal:  BMC Neurol       Date:  2021-02-10       Impact factor: 2.474

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.